Exploring how gut bacteria affect treatment outcomes in chronic myeloid leukemia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between gut microbiota and the effectiveness of Tyrosine Kinase Inhibitors (TKIs) in patients with Chronic Myeloid Leukemia (CML). It aims to identify specific microbial signatures that may correlate with better treatment responses, particularly in achieving deep molecular response (DMR). The study will analyze biological samples from CML patients to assess how variations in gut microbiota might influence treatment efficacy and contribute to side effects or metabolic disorders. By understanding these interactions, the research seeks to enhance patient outcomes and quality of life during TKI therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years old
* Chronic Myeloid Leukemia Patients
* Any stage of the disease

Exclusioni Criteria:

none

Where it's running

• AO Ordine Mauriziano di Torino
  Torino, Italy Recruiting

Study contacts

• Principal investigator: Carmen Fava — Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
• Study coordinator: Carmen Fava
• Email: carmen.fava@unito.it
• Phone: 00390115082224

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing biological age and frailty in newly diagnosed chronic leukemia patients for personalized treatment

  This study is testing how to personalize treatment for newly diagnosed chronic myeloid leukemia patients by looking at their biological age and overall health.

  Recruiting at 12 sites University Hospital, Clermont-Ferrand · Annecy and 16 other locations · NCT06130787

• Effect of Periodontal Therapy on Gut Microbes and Inflammation in People with Inflammatory Bowel Disease

  This study tests whether treating gum disease in people with inflammatory bowel disease can influence the gut microbiome and markers of systemic inflammation.

  Recruiting University of Turin, Italy · Turin, Turin · NCT07905859

• Brief psychological sessions with biofeedback for head and neck cancer surgery patients

  This pilot randomized study tests whether two short clinical psychology sessions with biofeedback can help reduce post-traumatic stress symptoms in adults undergoing demolitive surgery for head and neck cancer.

  Recruiting University of Turin, Italy · Turin · NCT07712120

• Biomarkers of Inflammation, Infection, and Immunity in Critically Ill Patients

  This study tests whether blood biomarkers can predict illness severity and complications in adults admitted to intensive care with infection, including sepsis, and in immunocompromised or high-risk surgical patients.

  Recruiting University of Turin, Italy · Torino · NCT07682766

• Unilateral versus bilateral extended pelvic lymph node dissection for men with unilateral high‑risk prostate cancer

  This test checks if removing lymph nodes only on the cancer side instead of both sides can keep cancer control while reducing complications for men with unilateral high-risk prostate cancer undergoing robot-assisted prostate removal.

  Recruiting University of Turin, Italy · Rozzano, Milano and 13 other locations · NCT07580196

• Oral urea to raise blood sodium in SIAD when fluid restriction fails

  This trial tests whether taking oral urea can raise blood sodium in people with chronic SIAD whose low sodium doesn't improve with fluid restriction.

  Recruiting University of Turin, Italy · Turin, Piedmont, Italy · NCT07528365

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.